drugset / Trial / NCT07235202
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
Non-randomizedSequentialOpen-labelTreatment
Summary
This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 Combined with Chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed after first-line therapy.
Timeline
- Start
- 2025-12-24
- Primary completion
- 2028-06-22
- Completion
- 2028-12-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MR001 | Unknown | 2 mg/kg | Intravenous |
| Subject | MR001 | Unknown | 4 mg/kg | Intravenous |
| Subject | MR001 | Unknown | 6 mg/kg | Intravenous |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Irinotecan Liposome Injection | Unknown | — | — |
| Background | LV | Unknown | — | — |
| Background | Nab-paclitaxel | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | — |